Australia markets closed
  • ALL ORDS

    7,690.70
    +41.40 (+0.54%)
     
  • AUD/USD

    0.7261
    -0.0001 (-0.01%)
     
  • ASX 200

    7,384.20
    +41.60 (+0.57%)
     
  • OIL

    75.45
    +1.47 (+1.99%)
     
  • GOLD

    1,751.00
    -0.70 (-0.04%)
     
  • BTC-AUD

    59,955.45
    -82.75 (-0.14%)
     
  • CMC Crypto 200

    1,082.86
    -20.20 (-1.83%)
     

Precision BioSciences to Report Second Quarter 2021 Financial Results on August 12, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

DURHAM, N.C., August 05, 2021--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that it will publish financial results for the second quarter 2021 and provide a business update on August 12, 2021.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its wholly proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple "off-the-shelf" CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210805005032/en/

Contacts

Investor Contact:
Alex Kelly
Chief Financial Officer
Alex.Kelly@precisionbiosciences.com

Media Contact:
Maurissa Messier
Senior Director, Corporate Communications
Maurissa.Messier@precisionbiosciences.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting